高危视网膜母细胞瘤3个周期与6个周期化疗比较:一项随机临床试验
这项双中心、随机、开放标签、非劣效性试验纳入187例单侧高危病理特征视网膜母细胞瘤眼球摘除术后患者,随机接受3个周期(94例)或6个周期(93例)CEV化疗。5年无病生存率3周期组90.4% vs 6周期组89.2%(差值1.2%,95%CI -7.5%至9.8%),满足非劣效标准(非劣效P=0.003)。6周期组不良事件更频繁、生活质量评分下降更大、费用更高。
要点
- 3周期CEV化疗5年无病生存率90.4%,6周期组89.2%,差值1.2%(95%CI -7.5%至9.8%),满足12%非劣效界值。
- 6周期组不良事件更频繁、生活质量评分下降更大、费用更高。
- 研究对象为单侧高危病理特征视网膜母细胞瘤眼球摘除术后患者。
核心结论
- 在单侧高危病理特征视网膜母细胞瘤患者中,3个周期CEV化疗的5年无病生存率非劣效于6个周期CEV化疗。
研究设计与样本
- 双中心、随机、开放标签、非劣效性试验,在中国2家顶级眼科中心开展,纳入2013年8月至2024年3月间因单侧视网膜母细胞瘤伴高危病理特征(广泛脉络膜浸润、筛板后视神经侵犯或巩膜浸润)行眼球摘除术的187例患者。
- 患者随机接受眼球摘除术后3个周期(n=94)或6个周期(n=93)CEV化疗方案。
- 全部187例患者完成试验,中位(IQR)年龄25.0(20.0-37.0)个月,女性83例(44.4%);中位(IQR)随访79.0(65.5-102.5)个月;末次随访日期为2024年3月21日。
主要发现
- 5年无病生存率3周期组为90.4%,6周期组为89.2%,差值1.2%(95%CI -7.5%至9.8%),满足非劣效标准(非劣效P=0.003)。
- 与3周期组相比,6周期组不良事件更频繁、生活质量评分下降更大、费用更高。
关键数值与推荐
- 主要终点为无病生存,非劣效界值为12%。
- 次要终点包括总生存、安全性、经济负担和儿童生活质量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Adjuvant therapy is an important and effective treatment for retinoblastoma. However, there is a lack of head-to-head clinical trials comparing 3 vs 6 cycles of CEV chemotherapy (carboplatin, etoposide, and vincristine) for enucleated unilateral retinoblastoma with high-risk pathological features. OBJECTIVE: To assess whether 3 cycles of CEV chemotherapy is noninferior to 6 cycles for enucleated unilateral retinoblastoma with high-risk pathological features. DESIGN, SETTING, AND PARTICIPANTS: This double-center, randomized, open-label, noninferiority trial was conducted at 2 premier eye centers in China and included 187 patients who had undergone enucleation for unilateral retinoblastoma with high-risk pathological features (massive choroidal infiltration, retrolaminar optic nerve invasion, or scleral infiltration) between August 2013 and March 2024. The final date of follow-up was March 21, 2024. INTERVENTIONS: Patients were randomly assigned to receive either 3 (n = 94) or 6 (n = 93) cycles of CEV chemotherapy regimen after enucleation. MAIN OUTCOMES AND MEASURES: The primary end point was disease-free survival, with a noninferiority margin of 12%. Secondary end points encompassed overall survival, safety, economic burden, and the quality of life of children. RESULTS: All 187 patients (median [IQR] age, 25.0 [20.0-37.0] months; 83 [44.4%] female) completed the trial. Median (IQR) follow-up was 79.0 (65.5-102.5) months. Five-year disease-free survival was 90.4% for the 3-cycle group vs 89.2% for the 6-cycle group (difference, 1.2% [95% CI, -7.5% to 9.8%]), which met the noninferiority criterion (P = .003 for noninferiority). The 6-cycle group experienced a higher frequency of adverse events, greater reduction in quality of life scores, and increased costs compared with the 3-cycle group. CONCLUSIONS AND RELEVANCE: Among patients with unilateral pathologic high-risk retinoblastoma, 3 cycles of CEV chemotherapy resulted in 5-year disease-free survival that was noninferior to 6 cycles of CEV chemotherapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01906814.
引用
- Ye H, Xue K, Zhang P, et al. Three vs 6 Cycles of Chemotherapy for High-Risk Retinoblastoma: A Randomized Clinical Trial. JAMA. 2024. PMID: 39432296. doi:10.1001/jama.2024.19981
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。